European Journal of Case Reports in Internal Medicine · Nov 19, 2026

Uncovering an insidious insulinoma with glucagon-like peptide-1 receptor agonist: a case report and review of the literature

By Lim KX, Tay SB, Cheong YLB et al.

Introduction: Insulinoma is a rare neuroendocrine tumour that secretes insulin resulting in hypoglycaemia. The initial diagnosis of insulinoma can be challenging in view of the intermittent and non-specific symptoms. Glucagon-like peptide-1 (GLP-1) receptor agonists are increasingly being prescribed for the treatment of diabetes mellitus and obesity. We discuss a case of how a GLP-1 receptor agonist unmasked a previously undiagnosed insulinoma. Case description: A 48-year-old woman with class III obesity was started on subcutaneous semaglutide, a GLP-1 receptor agonist, for weight management. After the initiation of semaglutide, she started having recurrent symptoms of hypoglycaemia that was initially unevaluated. The symptoms worsened when the patient developed an episode of gastroenteritis, which resulted in her fainting. Further work up of the hypoglycaemia revealed endogenous hyperinsulinaemia, with imaging confirming the diagnosis of an insulinoma. Insulinoma is known to overexpress GLP-1 receptors that bind to GLP-1 receptor agonists. Coupled with the caloric restriction from GLP-1 receptor agonist, exacerbated by acute gastroenteritis, this resulted in the patient presenting with recurrent symptomatic hypoglycaemia. Conclusion: GLP-1 receptor agonists can unmask previously asymptomatic insidious insulinomas. Since GLP-1 receptor agonist alone should rarely cause hypoglycaemia, a thorough evaluation is required to determine the underlying cause of this patient’s recurrent hypoglycaemia. This is especially important with the increasing usage of GLP-1 receptor agonists.

doi.org/10.12890/2026_007447Open accessInterventions

AgingResearch.News